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BRIEF DEFINITIVE REPORT
DCs have been studied extensively in the con-
text of immunity to tumors (for reviews see 
references  1, 2). Several studies have docu-
mented the increased infi  ltration of human tu-
mors by DCs and often correlated this with 
adverse prognosis (3–5). This has generally been 
interpreted in terms of the potential ability 
of tumor-infi  ltrating DCs to induce immune 
  tolerance. However, whether DCs interact 
more directly with human tumors/tumor 
  progenitor cells or alter their growth or diff  er-
entiation has not been described.
Multiple myeloma (MM) is a B cell tumor 
characterized by the clonal expansion of ma-
lignant plasma cells in the bone marrow (6). 
A typical feature of MM, which is responsible 
for the term “multiple” myeloma, is the mul-
tifocal growth of tumors in the bone marrow, 
illustrating the potential importance of spe-
cifi  c niches in the marrow. The tumor micro-
environment consists of several distinct 
elements, including immune eff  ector  cells, 
myeloid cells, bone cells, and fi  broblasts. 
However, most studies of the tumor micro-
environment in  myeloma have used ill- defi  ned 
stromal elements (6, 7). Therefore, the rela-
tive contribution of distinct elements of the 
microenvironment on the biology of tumor 
cells remains to be clarifi  ed.
Some studies have suggested a role for tumor-
associated macrophages in regulating the 
growth of tumors (5, 8). However DCs are bi-
ologically distinct from monocytes or macro-
phages and have unique functional properties 
(for review see reference 1). Prior studies have 
shown that DCs play an important role in nor-
mal B and plasma cell diff  erentiation and sur-
vival (9–11). Therefore, we hypothesized that 
DCs may also directly impact the growth and 
diff  erentiation of myeloma tumor cells.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
DCs enhance the clonogenicity of tumor cell 
lines in vitro
To test whether human DCs could alter the clo-
nogenic growth of human myeloma cell lines, 
we plated tumor cells alone or with purifi  ed 
monocytes or monocyte-derived DCs in methyl-
cellulose cultures. Plating tumor cells alone in 
this assay results in the growth of discrete tumor 
colonies with an effi   ciency  of   1% of cells 
plated. The addition of DCs to these cultures led 
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1859to a greater number of tumor colonies in a dose-dependent 
manner compared with tumor cells alone or cocultures with 
monocytes (Fig. 1, a–c). This growth-promoting eff  ect of DCs 
on human tumors is not restricted to myeloma, as the clono-
genic growth of two other tumors tested (lymphoma and breast 
cancer) was also enhanced (Fig. 1 d). In contrast, DCs had only 
a minor impact on the growth of glial tumors. The enhanced 
number of tumor colonies was mostly evident as an increased 
number rather than size of individual colonies, suggesting an 
eff  ect on cloning effi   ciency or survival (Fig. 1 e). Therefore, 
interactions of tumor cells and DCs can directly promote the 
clonogenicity of several but not all human tumors.
Coculture of myeloma cell lines with DCs leads 
to an increase in the CD138− subpopulation of tumor cells
The phenotype of tumor colonies in the clonogenic assay was 
monitored by fl   ow cytometric detection of CD138 and 
CD11c, and the presence of myeloma cells was identifi  ed by 
the presence of cells expressing the appropriate cytoplasmic Ig 
light chain (λ light chain in the case of U266 cells; Fig. 2 a). 
Flow cytometry data were also confi  rmed by immunofl  uo-
rescence microscopy (Fig. 2 b). The majority of the tumor 
cells in these cultures had a typical plasma cell phenotype 
with the expression of CD138 and light chain restriction. 
However, the culture of tumor cells in the presence of DCs 
led to a mild but consistent increase in the proportion of cells 
lacking CD138, a marker of terminally diff  erentiated plasma 
cells (Fig. 2 a). Upon immunofl  uorescence microscopy, tu-
mor cells grown in the presence of DCs were somewhat 
smaller in size with less cytoplasm compared with clonogenic 
cultures of tumor cells grown alone (Fig. 2 b). This is also ev-
ident as lower forward scatter of these tumors on fl  ow cy-
tometry (Fig. 2 c). Therefore, DC-mediated enhancement of 
myeloma clonogenicity is associated with an altered pheno-
type of tumors. A prior study has suggested that the CD138− 
subpopulation of MM cell lines is enriched for the clono-
genic growth in serial replating assays (12). Thus, we tested 
whether this altered phenotype was associated with en-
hanced clonogenicity in serial replating assays. Cells initially 
cultured with DCs had higher cloning effi   ciency in replating 
Figure 1.  Enhancement of the clonogenicity of human tumor cells 
by Mo-DCs. (a) Comparison of DCs versus monocytes. U266 myeloma 
tumor cells were plated with and without purifi  ed CD14+ monocytes or 
Mo-DCs in a clonogenic assay at a ratio of 1:2. (b) Myeloma cell lines 
(U266 and ARK) were plated with or without DCs at a ratio of 1:2 in a 
clonogenic assay. (a and b) The numbers of colonies were enumerated 
microscopically after 3 wk of culture. (c) U266 cells were plated with 
Mo-DCs at an increasing ratio of DC/tumor in a clonogenic assay. The 
numbers of tumor colonies were enumerated microscopically after an 
incubation of 3 wk. (a–c) Results are representative of three separate 
experiments. (d) Mantle cell lymphoma (NCEB1), breast cancer (MCF-7), or 
glioma (U251) cells were cultured alone or with DCs in a clonogenic assay. 
The numbers of tumor colonies were enumerated microscopically after 
3 wk of culture. Results are the mean ± SD (error bars) of the aggregate 
of three separate experiments. *, P < 0.05. (e) Appearance of colonies from 
a U266 myeloma cell line (top) or NCEB1 mantle cell lymphoma cell line 
(bottom) in the presence or absence of DCs. Micrographs show the 
  appearance of colonies in methylcellulose gels at low power.
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assays, suggesting that the observed alteration in phenotype is 
associated with the enhancement of clonogenicity (Fig. 2 d).
Mechanism of DC-mediated enhancement of clonogenicity
DC-mediated enhancement of tumor clonogenicity in this 
system required short-range interactions between tumor cells 
and DCs, as it was not evident when the two cell populations 
were separated in a Transwell (Fig. 3 a). To optimize cell–cell 
contact, we also evaluated the initial coculture of DCs and 
tumor cells in suspension culture for 24 h before plating them 
in methylcellulose. Adding this step led to a further increase 
in tumor colonies compared with direct cocultures, support-
ing the need for cellular proximity (Fig. 3 b). DCs express 
several molecules that are implicated in B cell diff  erentiation 
as well as costimulatory molecules and integrins that may be 
important for the observed eff  ects (11). We focused on two 
of these pathways involving TNF superfamily members. Both 
B cell–activating factor (BAFF)–APRIL (a proliferation-
  inducing ligand; references 13–15) and receptor activator of 
NF-kB (RANK)–RANK ligand (RANK-L) pathways (16) 
have been previously implicated in the survival of myeloma 
cells. Blockade of BAFF–APRIL-mediated interactions with 
TACI-Fc (transmembrane activator calcium modulator and 
cyclophilin ligand interactor-Fc chimera) or blockade of 
RANK–RANK-L–mediated interactions with osteoprote-
gerin (OPG; reference 17) led to the inhibition of DC-mediated 
enhancement of tumor clonogenicity in both myeloma 
cell lines tested (Fig. 3, c and d). This was also associated with 
less enrichment of the CD138− subpopulation in these co-
cultures (Fig. 3 e). TACI-Fc or OPG did not alter the clono-
genicity of tumor cells alone. We were unable to demonstrate 
a synergy between these ligands under the conditions tested. 
Therefore, DC-mediated enhancement of myeloma clono-
genicity is mediated, in part, by RANK-L and BAFF–
APRIL-mediated interactions.
DC-mediated changes in tumor cells
To gain insights into the early events during tumor–DC in-
teraction, we cocultured DCs and tumor cells for 24 h before 
separating tumor cells by FACS sorting to >99% purity and 
plated them in clonogenic assays without DCs. Tumor cells 
from these short cocultures demonstrated enhanced clono-
genic growth compared with mock-sorted tumor cells cul-
tured alone under similar conditions (Fig. 4 a). This suggested 
that even short-term interactions between tumor cells and 
DCs can alter the behavior of tumor cells. Pilot microarray 
experiments suggested B cell lymphoma 6 (BCL6) as one of 
the major genes consistently up-regulated in tumor cells pu-
rifi  ed from these cocultures (unpublished data). A prior study 
has suggested an important role for BCL6 in survival and self-
renewal of germinal center B cells (18). Thus, we analyzed 
the expression of BCL6 in these tumor cells by real-time 
RT-PCR (TaqMan) to confi  rm these results. Coculture of 
tumor cells with DCs was associated with an induction of 
BCL6 messenger RNA (mRNA) in sorted tumor cells com-
pared with tumors cultured alone (Fig. 4 b). This was also 
Figure 2.  Phenotypic evaluation of tumor colonies of clonogenic 
assays. (a) Tumor colonies from clonogenic assays were harvested and 
stained with various antibodies for fl  ow cytometric evaluation. U266 cells 
grown under different conditions (suspension culture, U266 alone, and 
with Mo-DCs in clonogenic assays) were analyzed after a 3-wk culture for 
the expression of cell surface CD138, CD11c, and intracellular Ig light 
chain. Data shown are gated for the live population. Numbers represent 
percentages of CD138−Igλ+ cells. Note that CD11c+ DCs are no longer 
evident at this time point. (b) Phenotype of CD138+ tumor cells in clono-
genic assays. Cytospins of tumor cells from cultures of tumor cells alone, 
or tumor–DC cocultures were stained with anti–CD138-PE and Igλ/Igκ-
FITC-AlexaFluor488 and analyzed by immunofl  uorescence microscopy. 
Red, CD138; green, Ig light chain (κ or λ); blue, DAPI nuclear stain. U266 
cells are λ light chain restricted. (c) Histogram of forward scatter (FSC) on 
fl  ow cytometric evaluation to analyze the size of tumor cells cultured as 
tumor cells alone or with DCs. (a–c) Results are representative of three 
separate experiments. (d) Enhanced clonogenicity of cells from tumor–DC 
cocultures. Tumor cells were harvested from the clonogenic assays of 
U266 cells originally plated with and without DCs (as in Fig. 1 b) and were 
serially replated without additional fresh DCs. The numbers of colonies 
were enumerated microscopically after a further incubation of 3 wk. 
  Results are representative of two separate experiments. Error bars represent 
SD. iDC, immature DC. *, P < 0.05.
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confi  rmed at the protein level by immunofl  uorescence mi-
croscopy. U266 tumor cells cultured alone do not express 
BCL6; however, clear intranuclear staining for BCL6 was 
observed in tumor cells cocultured with DCs (Fig. 4 c). As 
TACI-Fc and OPG inhibited the DC-mediated enhance-
ment of tumor clonogenicity, we also tested their eff  ect on 
BCL6 up-regulation. The addition of TACI and OPG led to 
the modest but detectable inhibition of DC-mediated BCL6 
mRNA up-regulation in tumor cells (Fig. 4 d). Therefore, 
the short-term coculture of DCs and tumor cells is associated 
with an up-regulation of BCL6 on tumor cells.
DCs enhance the clonogenic growth of primary 
myeloma cells
To extend these observations on cell lines to primary cells 
from patients, we obtained bone marrow samples from 
patients with myeloma and preneoplastic gammopathy 
(MGUS). A prior study has shown that clonogenic growth of 
tumor cells is enriched in CD34−CD138− subpopulations 
(12). Bone marrow mononuclear cells (MNCs) from my-
eloma (n = 9) or MGUS (n = 3) patients were separated into 
CD138+ and CD34−CD138− subpopulations and cultured 
in the presence or absence of autologous or allogeneic DCs 
in clonogenic assays. The addition of DCs to these subpopu-
lations led to a more than twofold enhancement of tumor 
colonies from the CD34−CD138− fraction in 4/5 patients 
(two MGUS and three MM) using autologous DCs and 
7/11 patients (two MGUS and nine MM) using allo-
geneic DCs (Fig. 5, a and b). There were no major diff  er-
ences between MGUS and myeloma samples. To further 
assess their clonogenicity, tumor cells harvested from some of 
these assays were replated in fresh assays. Tumor cells could 
Figure 3.  Mechanism of DC-mediated enhancement of the clono-
genic growth of tumor cells. (a) Requirement for cell–cell contact. 
U266 cells were plated in the clonogenic assay with or without DCs as in 
Fig. 1. DCs were either plated along with U266 cells (DC/tumor ratio of 
2:1) or separated from U266 cells by a Transwell insert. Data are represen-
tative of three similar experiments. (b) The myeloma cell line (U266) was 
cocultured with Mo-DCs at a ratio of 1:2 overnight in suspension culture 
in a 96-well plate (suspension primed) before plating in a clonogenic 
assay and was compared with cell lines plated directly with and without 
Mo-DCs as in Fig. 1 b. Results are representative of two separate experi-
ments. (a and b) The numbers of colonies were enumerated after 3 wk. 
(c and d) Tumor cells (U266 and ARK) and Mo-DCs were cultured in the 
presence of 1 μg/ml TACI-Fc,0.5 μg/ml osteoprotegerin (OPG), or 1 μg/ml 
CD28-Fc chimera as a control. The numbers of colonies for U266 (c) and 
ARK (d) were enumerated microscopically after an incubation of 3 wk. 
Data are representative of three similar experiments. (e) Tumor cells were 
harvested from clonogenic assays of U266 cells cocultured with DCs in 
the presence or absence of 1 μg/ml TACI-Fc and 0.5 μg/ml OPG at the 
end of 3 wk of incubation and were characterized using fl  ow cytometry. 
Cells were stained for cell surface CD138 (PE) and intracellular Ig light 
chain (FITC). Data shown are gated for the live population and represents 
the percent decrease in CD138− cells in cocultured tumor cells in the 
presence of TACI and OPG compared with the control cultures without 
TACI/OPG. Error bars represent SD. *, P < 0.05.JEM VOL. 203, August 7, 2006  1863
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be successfully passaged in serial assays from both subpopula-
tions (Fig. 5 c). Importantly, coculture with DCs allowed 
clonogenic growth even from the purifi  ed CD138+ subpop-
ulation from myeloma patients, which normally does not 
grow well in vitro by itself (12). Therefore, DCs lead to the 
enhanced clonogenic growth of primary tumor cells from 
myeloma patients, and this coculture system may be a useful 
model system for the growth of primary myeloma cells.
Most human tumors recruit diverse immune cells, includ-
ing DCs, to the tumor bed. However, infi  ltration of human 
tumors by DCs has previously been interpreted largely in the 
context of their immunologic functions (4, 5). Prior studies 
have shown that both myeloma tumors in patients and mouse 
plasmacytomas are extensively infi  ltrated by DCs (19, 20), 
accounting for up to 10% of all nucleated cells within these 
lesions. Our data suggest the possibility that tumor-infi  ltrating 
DCs may provide a niche to support the clonogenic growth 
of human myeloma without the need to invoke a viral 
  infection (20). DC-mediated enhancement of tumor clono-
genicity may also involve other tumor types, such as 
  lymphoma and breast cancer. Interestingly, a recent study of 
gene expression profi  les of lymphoma has shown that the 
presence of DC signature in lymphoma portends an adverse 
outcome, which is consistent with these results (21). How-
ever, the involved mechanisms, which are only studied for 
myeloma here, may diff  er between diff  erent tumor types.
In our studies, blockade of the RANK–RANK-L path-
way by OPG or blockade of BAFF–APRIL-mediated inter-
actions via TACI-Fc led to the inhibition of DC-mediated 
enhancement of the clonogenicity of human myeloma. These 
Figure 4.  Effect of DCs on tumor cells during tumor–DC cocultures. 
(a) Tumor cells (U266) were cocultured with Mo-DCs overnight at a 
ratio of 1:2 in suspension culture in a 96-well plate before sorting 
CD138+ tumor cells by fl  ow cytometry. U266 cells cultured alone were 
mock sorted as a control. Sorted tumor cells were plated in clonogenic 
assays and were compared with untreated U266 cells. The numbers of 
colonies were enumerated after 3 wk. Error bars represent SD. *, P < 0.05. 
(b) U266 tumor cells were cultured alone or with pure populations of DCs 
at a tumor/DC ratio of 1:2. After 24 h, CD138+ tumor cells were sorted by 
fl  ow cytometry to >99% purity. The expression of BCL6 mRNA in purifi  ed 
tumor cells was analyzed by real-time RT-PCR (TaqMan) and normalized 
to the expression of the housekeeping gene GAPDH. (c) Immunofl  uores-
cence analysis of BCL6 protein in U266 tumor cells cultured alone or with 
DCs. Acetone-fi  xed cells on poly-lysine–coated slides were stained with 
anti-BCL6 mAb followed by AlexaFluor488 and CD138 (PE). DAPI was used 
as a nuclear stain. Note the intranuclear staining for BCL6 in tumor cells 
from tumor–DC cocultures. Arrows indicate cells expressing intranuclear 
BCL6. (d) U266 tumor cells were cultured alone or with pure populations 
of DCs at a tumor/DC ratio of 1:2 in the presence or absence of 1 μg/ml 
TACI and 0.5 μg/ml OPG. Cells cultured in the presence of IgG1 were used 
as controls. After 24 h, CD138+ tumor cells were sorted by fl  ow cytometry 
to >99% purity. The expression of BCL6 mRNA in purifi  ed tumor cells was 
analyzed by real-time RT-PCR (TaqMan) and normalized to the expression 
of the housekeeping gene GAPDH. The effect of TACI + OPG on DC-
  induced BCL6 expression in tumor cells was analyzed as the percent 
change compared with control cocultures.
Figure 5.  Enhancement of the clonogenicity of bone marrow–
derived CD138+ and CD138− cells from myeloma and MGUS pa-
tients by Mo-DCs. (a and b) CD138+ and CD138−CD34− cells harvested 
from bone marrow MNCs were plated with and without autologous/ 
allogeneic Mo-DCs at a ratio of 1:2 in the clonogenic assays. (a) Repre-
sentative data from an MGUS patient with autologous DCs. (b) Summary 
of data from 12 patients showing the fold increase in tumor colonies with 
autologous or allogeneic DCs compared with CD138−CD34− cells alone. 
(c) Effect of serial replating. Colonies were harvested from clonogenic 
assays as in panel a and were replated with fresh Mo-DCs at a ratio of 
1:2. Data shown are representative of experiments of two myeloma 
  patients. (a–c) The numbers of colonies were enumerated microscopically 
after an incubation of 3 wk. Error bars represent SD. 1864  DCS PROMOTE TUMOR GROWTH | Kukreja et al. 
data are consistent with prior studies showing the impor-
tance of both of these pathways in myeloma biology and 
point to DCs as an important source of these ligands (11, 
13, 15). However, our data does not exclude the possibility 
that other molecules such as integrins or costimulatory mole-
cules commonly expressed on DCs may also be important in 
DC–myeloma interactions. Additional mechanisms of the 
DC-mediated regulation of myeloma growth may include 
the potential contribution of tumor-associated DCs as pre-
cursors to new blood vessels (22) or osteoclasts (23). Indeed, 
a recent study has shown that osteoclasts can also support the 
growth of myeloma cells in vitro (24).
The culture of U266 cells with DCs led to an increased 
proportion of Igλ+ cells lacking CD138, a marker of terminal 
plasma cell diff  erentiation, as well as induction of BCL6 ex-
pression in tumor cells. Suppression of BCL6 is a critical fea-
ture of normal plasma cell diff   erentiation. These data are 
reminiscent of the fi  ndings of a previous study that observed 
the reactivation of the B cell program after exogenous ex-
pression of BCL6 in myeloma cell lines (25). Together, these 
data suggest that the diff  erentiation state of myeloma cells is 
plastic and can be modifi  ed by cues provided by DCs in the 
tumor bed.
To our knowledge, these data provide the fi  rst evidence 
that DCs can directly impact the clonogenic growth of hu-
man tumors. Therefore, the recruitment of DCs into tu-
mors may impact not just the host immune response but also 
the biology of the tumor itself. In a prior study, we have 
shown that the eff   ector function of tumor-infi  ltrating  T 
cells correlates with favorable clinical features in MGUS 
versus myeloma (26). Thus, the immune system may be a 
two-edged sword, with distinct components capable of both 
supporting and inhibiting tumor growth. Identifi  cation of 
tumor-infi  ltrating DCs as potential contributors to tumor 
progression also provides the rationale for specifi  cally target-
ing this interaction as a novel approach for the therapy of 
human cancer.
MATERIALS AND METHODS
Tumor cell lines and patient samples. The human MM cell lines ARK 
(gift from J. Epstein, University of Arkansas, Little Rock, AR) and U266 
(American Type Tissue Culture) were cultured in complete medium consist-
ing of RPMI 1640 (Cellgro), 2 mM l-glutamine, 20 μg/ml gentamicin sulfate, 
and 10% FBS. Other tumor cell lines used were NCEB1 (mantle cell lym-
phoma; gift of O. O’Connor, Memorial Sloan Kettering Cancer Center 
[MSKCC], New York, NY), MCF-7 (breast cancer; gift of P. Livingston, 
MSKCC), and U251 (glioma; gift of R. Puri, Food and Drug Administration, 
Bethesda, MD). Bone marrow and blood specimens from patients with my-
eloma and MGUS were obtained after informed consent that was approved by 
The Rockefeller University Institutional Review Board (IRB).
Generation of DCs. Peripheral blood samples were obtained from healthy 
donors after informed consent as approved by The Rockefeller University 
IRB or were purchased from the New York Blood Center. PBMCs were 
isolated by density gradient centrifugation (Ficoll-Paque Plus; GE Health-
care). DCs were generated from purifi  ed blood monocytes as described pre-
viously (27). In brief, monocytes isolated using CD14 microbeads (Miltenyi 
Biotec) were cultured in the presence of 20 ng/ml GM-CSF (Immunex) and 
10 ng/ml IL-4 (R&D Systems). DCs were used on days 5–6 of culture.
Clonogenic assays. Clonogenic growth of tumor cell lines was evaluated 
by plating tumor cells (50,000 cells/ml) in methylcellulose containing 5% 
leukocyte-conditioned media (Methocult; Stem Cell Technologies, Inc.) 
  using a protocol modifi  ed from a previous study (12). Cells were plated in 
35-mm2 tissue culture dishes in quadruplicates and incubated at 37°C and 5% 
CO2. Colonies consisting of >40 cells were counted by microscopy 2–3 wk 
after plating.
DC–myeloma interactions. To assess the impact of monocytes/DCs on 
tumor clonogenicity, tumor cells were mixed with purifi  ed CD14+ mono-
cytes or monocyte-derived DCs (Mo-DCs) at varying ratios before plating 
in Methocult. Tumor growth was monitored weekly. For cell contact–
  dependent assays, DCs were suspended in 2% IMDM and were separated 
from U266 cells by a Transwell insert. Control inserts had 2% IMDM only. For 
some experiments, tumor cells and DCs were cultured in the presence or 
absence of either 1 μg/ml TACI-Fc (R&D Systems) or 0.5 μg/ml OPG     
(R&D Systems). CD28-Fc protein (R&D Systems) was used as a control.
Clonogenic assays on primary tumor cells. Bone marrow MNCs were 
isolated from marrow samples using density gradient centrifugation.  For 
clonogenic assays on primary tumor cells from patients, CD138+ and 
CD138− fractions were isolated from bone marrow MNCs using CD138 
microbeads (Miltenyi Biotec) and AutoMACS (Miltenyi Biotec). The 
CD138− fraction was further depleted of normal hematopoietic progenitors 
using CD34 microbeads (Miltenyi Biotec). The resulting fractions, CD138+, 
and CD138−CD34− cells (5 × 105/ml) were plated with or without Mo-
DCs at a ratio of 1:2 in Methocult as described above for cell lines. Tumor 
colonies were scored at 2 wk of culture. The phenotype of tumor cells was 
confi  rmed by immunofl  uorescence microscopy. For replating assays, cells 
were harvested from the clonogenic assays, washed, and replated at original 
cell concentration with or without DCs at a tumor/DC ratio of 1:2. Colo-
nies were scored after 2 wk of culture.
Flow cytometric evaluation of tumor colonies in clonogenic assays. 
Tumor colonies harvested from clonogenic assays were analyzed for the cell 
surface expression of CD138-PE, CD11c-APC, and intracellular κ or λ light 
chain–FITC (BD Biosciences) by fl  ow cytometry.
Immunofl  uorescence  microscopy. Cytospins were made on the poly-
  lysine–coated (Sigma-Aldrich) multiwell slides (Carlson Scientifi  c). Cells were 
fi  xed with acetone and stained with primary and secondary antibodies for 
30 min at room temperature. Primary antibodies CD138 (PE), Igλ, and Igκ 
(BD Biosciences) and the secondary antibody AlexaFluor488 goat anti–
mouse IgG1 (Invitrogen) were used at 1:30 and 1:200 dilutions, respectively. 
Acetone-fi  xed cytospins of tumor cells were also stained for BCL6 mAb (clone 
P1F6+PG-B6p; Lab Vision Corp.) followed by AlexaFluor488 goat anti–
mouse IgG1 (Invitrogen) and CD138 (PE) using the protocol described previ-
ously with few modifi  cations (28). Slides were evaluated using an epifl  uorescence 
microscope (AX70; Olympus) with a motorized stage to allow 0.5-mm optical 
sections imaged with a cooled CCD camera (C4742-95; Hamamatsu) and 
  analyzed with MetaMorph software (Universal Imaging Corp.).
Evaluation of BCL6 expression in tumor cells by TaqMan. RNA was 
extracted from cells by using the RNeasy Mini Kit (QIAGEN). BCL6 ex-
pression was quantifi  ed by using Assays-on-Demand primer probes from 
Applied Biosystems. RT-PCR was performed by using EZ PCR Core Re-
agents (Applied Biosystems) according to the manufacturer’s instructions. 
A BCL6-expressing plasmid (provided by K. Calame, Columbia University, 
New York, NY) was used as a positive control. The samples were amplifi  ed 
and quantifi  ed on a sequence detection system (PRISM 7700; Applied Bio-
systems) by using the following thermal cycler conditions: 2 min at 50°C, 
30 min at 60°C, 5 min at 95°C, and 40 cycles of 15 s at 95°C followed by 60 s 
at 60°C. GAPDH, a housekeeping gene, was used to normalize each sample. 
The data were analyzed, and samples were quantifi  ed by the software pro-
vided with the Applied Biosystems PRISM 7700.JEM VOL. 203, August 7, 2006  1865
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Statistical analysis. Data from diff  erent experimental groups were com-
pared using the Students’ t test, and signifi  cance was set at P < 0.05.
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